Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance

Muraoka, Daisuke; Seo, Naohiro; Hayashi, Toshiya; Tahara, Yoshiro; Fujii, Keisuke; Tawara, Isao; Miyahara, Yoshihiro; Okamori, Kana; Yagita, Hideo; Imoto, Seiya; Yamaguchi, Rui; Komura, Mitsuhiro; Miyano, Satoru; Goto, Masahiro; Sawada, Sumiyuki; Asai, Akira; Ikeda, Hiroaki; Akiyoshi, Kazunari; Harada, Norihiro; Shiku, Hiroshi

doi:10.1172/jci97642

Cited by 117 publications

(96 citation statements)

References 82 publications

(101 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although TAMs are largely immunosuppressive, specific subsets may also promote anti-tumor immunity [ 11 , 31 ]. These M1-like TAMs produce IFNγ, express high levels of both major histocompatibility complex (MHC)-II and costimulatory molecules and secrete chemokines and cytokines (e.g., CXCL9, CXCL10, IL-18, IL-22) that boost Th1 and NK cells’ pro-inflammatory and anti-tumoral activity [ 43 , 46 , 47 ]. In this view, re-educating TAMs to acquire anti-tumor functions represents an attractive strategy to alleviate the immunosuppressive features of TME and to promote tumor regression [ 17 ].…”

Section: Tumor-associated Myeloid Cellsmentioning

confidence: 99%

Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad

Bleve

Durante

Sica

et al. 2020

IJMS

View full text Add to dashboard Cite

Cancer progression generates a chronic inflammatory state that dramatically influences hematopoiesis, originating different subsets of immune cells that can exert pro- or anti-tumor roles. Commitment towards one of these opposing phenotypes is driven by inflammatory and metabolic stimuli derived from the tumor-microenvironment (TME). Current immunotherapy protocols are based on the reprogramming of both specific and innate immune responses, in order to boost the intrinsic anti-tumoral activity of both compartments. Growing pre-clinical and clinical evidence highlights the key role of metabolism as a major influence on both immune and clinical responses of cancer patients. Indeed, nutrient competition (i.e., amino acids, glucose, fatty acids) between proliferating cancer cells and immune cells, together with inflammatory mediators, drastically affect the functionality of innate and adaptive immune cells, as well as their functional cross-talk. This review discusses new advances on the complex interplay between cancer-related inflammation, myeloid cell differentiation and lipid metabolism, highlighting the therapeutic potential of metabolic interventions as modulators of anticancer immune responses and catalysts of anticancer immunotherapy.

show abstract

Section: Tumor-associated Myeloid Cellsmentioning

confidence: 99%

Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad

Bleve

Durante

Sica

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…An important role has also been reported in determining ICIs resistance by tumor associated macrophages (TAMs). In particular, Muraoka et al demonstrated that in immune-resistant tumors, TAMs remained inactive and did not serve as antigen-presenting cells, and their manipulation, by inducing their antigen-presenting activity, could re-sensitize cells to treatment [59]. Moreover, TAMs enhance tumor hypoxia and aerobic glycolysis, contributing to resistance to therapy.…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers

Pasini

Ulivi

2019

JCM

View full text Add to dashboard Cite

The use of targeted agents and immunotherapy for the treatment of advanced non-small-cell lung cancer (NSCLC) has made it mandatory to characterize tumor tissue for patient selection. Moreover, the development of agents that are active against specific resistance mechanisms arising during treatment make it equally important to characterize the tumor tissue at progression by performing tissue re-biopsy. Given that tumor tissue is not always available for molecular characterization due to the paucity of diagnostic specimens or problems relating to the carrying out of invasive procedures, the use of liquid biopsy represents a valid approach to overcoming these difficulties. The most common material used for liquid biopsy in this setting is plasma-derived cell free DNA (cfDNA), which originates from cells undergoing apoptosis or necrosis. However, other sources of tumor material can be considered, such as extracellular vesicle (EV)-derived nucleic acids, which are actively secreted from living cells and closely correspond to tumor dynamics. In this review, we discuss the role of liquid biopsy in the therapeutic management of NSCLC with particular regard to targeted therapy and immunotherapy, and analyze the pros and cons of the different types of samples used in this context.

show abstract

“…The CHP nanogel acted as a protein delivery carrier, and showed immune-stealth ability by preventing interactions with non-antigen-presenting cells because of its highly hydrophilic surface. 16 We further conrmed that the CHP nanogel induced Th1 immune system activation and exhibited anti-tumor efficacy as a cancer therapeutic vaccine, 17,18 and CHP nanogel vaccines with HER-2 or NY-ESO-1 antigens have shown novel cancer therapeutic effect in clinical trials. 19,20 The CHP nanogel effectively delivered antigens to lymph nodes and enabled activation of CTLs through cross-presentation of antigen-presenting cells including CD169 + macrophages.…”

Section: Introductionmentioning

confidence: 79%

Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance

Cited by 117 publications

References 82 publications

Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad

Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad

Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers

Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody

Contact Info

Product

Resources

About